{"organizations": [], "uuid": "e54d99c41f010f359f908b2721930369e3c29471", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-insys-therapeutics-announces-exclu/brief-insys-therapeutics-announces-exclusive-license-partnership-to-commercialize-subsys-in-middle-east-idUSFWN1SF1AD", "country": "US", "domain_rank": 408, "title": "BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.949, "site_type": "news", "published": "2018-05-09T06:51:00.000+03:00", "replies_count": 0, "uuid": "e54d99c41f010f359f908b2721930369e3c29471"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-insys-therapeutics-announces-exclu/brief-insys-therapeutics-announces-exclusive-license-partnership-to-commercialize-subsys-in-middle-east-idUSFWN1SF1AD", "ord_in_thread": 0, "title": "BRIEF-Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East", "locations": [], "entities": {"persons": [{"name": "jordan", "sentiment": "none"}, {"name": "lunatus", "sentiment": "none"}], "locations": [{"name": "middle east", "sentiment": "none"}, {"name": "insys", "sentiment": "none"}, {"name": "qatar", "sentiment": "none"}, {"name": "lunatus", "sentiment": "none"}, {"name": "lebanon", "sentiment": "none"}, {"name": "bahrain", "sentiment": "none"}, {"name": "kuwait", "sentiment": "none"}, {"name": "oman", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - INSYS Therapeutics Inc:\n* INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST\n* INSYS - CO’S RESPONSIBILITIES WILL INCLUDE SUPPLYING SUBSYS TO LUNATUS, WHOSE RESPONSIBILITIES WILL INCLUDE OBTAINING APPROVALS TO COMMERCIALIZE SUBSYS\n* INSYS - LUNATUS WILL BE EXCLUSIVE LICENSEE FOR SUBSYS IN BAHRAIN, JORDAN, KUWAIT, LEBANON, OMAN, QATAR, SAUDI ARABIA AND UNITED ARAB EMIRATES Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T06:51:00.000+03:00", "crawled": "2018-05-09T12:24:21.002+03:00", "highlightTitle": ""}